-
-
-
[1] EBY C S.Bleeding and thrombosis risks in plasma cell dyscrasias[J].Hematol Am Soc Hematol Educ Program,2007,2007:158-164.
[2] SUSUMN S.IgA pyroglobulin,Hyperviscosity syndrome and coagulation abnormality in a patient with multiple myeloma[J].Blood,1972,39:224-237.
[3] PANZER S,THALER E.An acquired cryoglogulinemia which inhibits fibrin polymerization in a patient with IgG kappa myeloma[J].Haemostasis,1993,23:69-76.
[4] AUWERDA J J,SONNEVELE P,DE MAAT M P,et al.Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma[J].Haematologica,2007,92:279-280.
[5] SARI I,ERKURT M A,IFARAN A,et al.Multiple myeloma presenting with acquired factor Ⅷ inhibitor[J].Int J Hematol,2009,90:166-169.
[6] HOLME P A,BROSSTAD F,TJONNFJORD G E.Acquired hemophilia:management of bleeds and immune therapy to eradicate auto-antibodies[J].Haemophilia,2005,11:510-515.
[7] MOHRI H,NOQUCHI T,KODAMA F,et al.Acquired von willebrand disease due to inhibitor of human myeloma protein specific for von Willebrand Factor[J].Am J Clin Parhol,1987,87:663-668.
[8] STRICKER R B,BARLOQIE B,KIPROV D D.Acquired factor Ⅷ inhibitor associated with chronic interferon-alpha therapy[J].J Rheumatol,1994,21:350-352.
[9] CESARMAN-MAUS G,BRAQQIO E,MALDONADO H,et al.Absence of tissue factor expression by neoplastic plasma cells in multiple myeloma[J].Leukemia,2012,15:1-4.
[10] 于阳,王轩,包芳,等.多发性骨髓瘤并获得性凝血因子Ⅺ及Ⅸ缺乏首例报告[J].临床误诊误治,2011,24(12):51-53.
[11] ELICE F,FINK L,TRICOT G,et al.Acquired resistance to activated protein C(aAPCR)in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism[J].Br J Haematol,2006,134:399-405.
[12] DEITCHER S R,ERBAN J K,LIMENTANI S A.Acquired free protein S deficiency associated with multiple myeloma:a case report[J].Am J Hematol,1996,51:319-323.
[13] YAGCI M,SUCAK G T,HAZNEDAR R.Fibrinolytic activity in multiple myeloma[J].Am J Hematol,2003,74:231-237.
[14] VAN MARION A M,AUWERDA J J,MINNEMA M C,et al.Hypfibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis[J].Thromb Haemost,2005,94:1341-1343.
[15] SANE D,PIZZO S,GREENBERG C.Elevated urokinase-type plasminogen activator level and bleeding in amyloidosis:case report and literature review[J].Am J Hematol,1989,31:53-57.
[16] PALMER R,RICK M,RICK P,et al.Circlulating heparan sulfate anticoagulant in a patient with a fatal bleeding disorder[J].N Engl J Med,1984,310:1696-1699.
[17] LLAMAS P,OUTEIRINO J,SANTOS A,et al.Report of three cases of circulating heparin-like anticoagulants[J].Am J Hematol,2001,67:256-258.
[18] BALCIK O S,ALBAYRAK M,UYAR M E,et al.Serum thrombin activtable fibrinolysis inhibitor levels in patients with newly diagnosed multiple myeloma[J].Blood Coagul Fibrinolysis,2011,22:260-263.
[19] EL ACCAOUI R N,SHAMSEDDEEN W A,TAHER A T.Thalidomide and thrombosis.A metaanalysis[J].Thromb Haemost,2007,97:1031-1036.
[20] RICHARDSON P G,BLOOD E,MITSIADES C S,et al.A randomized phase 2 study of lenalidomide therapy for patients with relapsed or refractory multiple myeloma[J].Blood,2006,108:3458-3464.
[21] RICHARDSON P,JAGANNATH S,HUSSEIN M,et al.Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma[J].Blood,2009,114:772-778.
[22] ZONDER J A,BARLOGIE B,DURIE B G,et al.Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone:benefit of aspirin prophylaxis[J].Blood,2006,108:403-403.
[23] RAJKUMAR S V,JACOBUS S,CALLANDER N S,et al.Lenalidomid plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma:an open-label randomized controlled trial[J].Lancet Oncol,2010,11:29-37.
[24] JOHNSON D C,CORTHALS S,RAMOS C,et al.Genetic associations with thalidomide mediated venous thromboembolic events in myeloma identified using targeted genotyping[J].Blood,2008,112:4924-4934.
[25] AVCU F,URAL A U,CETIN T,et al.Effects of bortezomib on platelet aggregation and ATP release in human platelets,in vitro[J].Thromb Res,2008,121:567-571.
[26] ZANGARI M,GUERRERO J,CAVALLO F,et al.Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma[J].Haematologica,2008,93:953-954.
[27] HIROI T,DEMING C B,ZHAO H,et al.Proteasome inhibitors enhance endothelial thrombomodulin expression via induction of Kruppel-like transcription factors[J].Arterioscler Thromb Vasc Biol,2009,29:1587-1593.
[28] SHEN Y,ZHOU X,WANG Z,et al.Coagulation profiles and thromboembolic events of bortezomib plus thalidomide and dexamethasone therapy in newly diagnosed multiple myeloma[J].Leuk Res,2011,35:147-151.
[29] SNOWSEN J A,AHMEDZAI S H,ASHCROFt J,et al.Guidelines for supportive care in multiple myeloma 2011[J].Br J Haematol,2011,154:76-103.
-
计量
- 文章访问数: 149
- PDF下载数: 169
- 施引文献: 0
下载: